Alkermes Launches Phase 2 Study of ALKS 7290
Alkermes has started a Phase 2 study of ALKS 7290 as adjunctive therapy to antidepressants in patients with major depressive disorder.
Alkermes has started a Phase 2 study of ALKS 7290 as adjunctive therapy to antidepressants in patients with major depressive disorder.